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Abstract
Aims Heart failure with preserved ejection fraction (HFpEF) poses a substantial challenge for clinicians, but there is little
guidance for effective management. The aim of this systematic review was to determine if there was evidence that disease
management programmes (DMPs) improved outcomes for patients with HFpEF.
Methods and results A systematic review of controlled studies in English or Greek of DMPs including patients with HFpEF
from 2008 to 2018 was conducted using CINAHL, Cochrane, MEDLINE, and Embase. Interventions were assessed using a
DMP taxonomy and scored for complexity and intensity. Bias was assessed using the Cochrane Collaboration tool. Initial
and updated searches found 6089 titles once duplicates were removed. The final analysis included 18 studies with 5435 HF
patients: 1866 patients (34%, study ranges 18–100%) had potential HFpEF (limited by variable definitions). Significant hetero-
geneity in terms of the population, intervention, comparisons, and outcomes prohibited meta-analysis. Statistically significant
or positive trends were found in mortality, hospitalization rates, self-care ability, quality of life, anxiety, depression, and sleep,
but findings were not robust or consistent. Four studies reported results separately for study-defined HFpEF, with two finding
less positive effect on outcomes.
Conclusions Varying definitions of HFpEF used in studies are a substantial limitation in interpretation of findings. The re-
duced efficacy noted in contemporary HF DMP studies may not only be due to improvements in usual care but may also reflect
inclusion of heterogeneous patients with HFpEF or HF with mid-range EF who may not respond in the same way as HFrEF to
individual components. Given that patients with HFpEF are older and multi-morbid, DMPs targeting HFpEF should not rely on a
single-disease focus but provide care that addresses predisposing and presentation phenotypes and draws on the principles of
comprehensive geriatric assessment. Other components could also be more targeted to HFpEF such as modification of lifestyle
factors for which there is emerging evidence, rather than simply continuing the model of care used in HFrEF. Based on current
evidence, HF DMPs may improve mortality, hospitalization rates, self-care, and quality of life in patients with HFpEF; however,
further research specifically tailored to appropriately defined HFpEF is required.
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Introduction
Heart failure with preserved ejection fraction (HFpEF) is an in-
creasingly prevalent condition that poses a substantial chal-
lenge for clinicians. Despite composing half of all patients
with heart failure (HF), it remains less well recognized and
understood.1,2 Patients with HFpEF are more likely to be
older, female, and have multiple co-morbid conditions, and
no drugs have yet been shown to improve morbidity and
mortality.3,4 Symptom burden and adverse outcomes are
similar to patients with HF with a reduced ejection fraction
(HFrEF).5,6 Analysis of a large cohort of hospitalized patients
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with HFpEF (n = 53 065) found a 30 day and 1 year all-cause
readmission rate of 22% and 67% respectively and a compos-
ite all-cause readmission and mortality rate of 74.5% at 1
year.7 Current recommendations for management of HFpEF
are to control cardiovascular and non-cardiovascular co-mor-
bidities and use diuretics to manage fluid status.8 Although
multi-disciplinary team (MDT) disease management
programmes to reduce the risk of hospitalization and mortal-
ity are recommended for patients with HF, there is little infor-
mation about their effectiveness specifically in HFpEF.8
Disease management programmes (DMP) are designed to
‘improve outcomes through structured follow-up with pa-
tient education, optimization of medical treatment, psycho-
social support and improved access to care’.9 Most HF
DMPs in the 1990s–early 2000s focused on patients with
HFrEF10 usually after an HF hospitalization. Outcomes for pa-
tients with HFrEF were improved through multi-component
DMPs that included the following: optimization of evidence-
based treatment (emphasis on medications for HFrEF), edu-
cation, behaviour change, supported self-management, and
clinician monitoring. In previous systematic reviews, HF DMPs
were found to significantly reduce HF hospitalizations, and
those with continued specialized follow-up reduced all-cause
mortality and all-cause hospitalization.10,11 However, some
reviews have found limited or no benefit, especially in studies
after 2008, in studies with <3 months of follow-up, or in pa-
tients without a recent hospitalization.12,13
In HF DMPs, it can be challenging to ascertain if the sample
included patients with HFpEF, given relatively recent use of
the term and controversies over diagnostic criteria. HFrEF is
a more tempting target because of robust evidence for spe-
cific pharmacological therapies in reducing mortality and
morbidity. Thus, little is known about the use and effective-
ness of HF DMPs in patients with HFpEF in improving out-
comes. The aim of this analysis was to determine if there
was evidence that HF DMPs improved outcomes specifically
for patients with HFpEF.
The review questions were as follows:
• Do MDT or nurse-led DMPs for patients with HFpEF result
in better outcomes for patients compared with usual care
or another intervention?
• What are the components and processes of successful
MDT or nurse-led DMPs for patients with HFpEF?
Methods
The review protocol was registered on Prospero (http://
www.crd.york.ac.uk/PROSPERO/display_record.php?ID=
CRD42017067980). The systematic review was conducted
and reported in accordance to the PRISMA guidelines
(http://www.prisma-statement.org/). The years 2008 to
2018 were chosen to reflect contemporary management of
HF, increasing attention to HFpEF, and recommendations
for HF DMPs in guidelines for management of HF.14 Language
was restricted to English or Greek. Studies of community-
dwelling adults with HFpEF were included, as were studies
with a mixed HF population if the proportion of patients with
HFpEF was discernible, and represented approximately 20%
or greater of the total sample. The intervention had to be
an MDT or nurse-led outpatient DMP with a minimum of 3
months of follow-up and a control group for comparison. Sin-
gle interventions composed only of pharmacotherapy, exer-
cise, invasive monitoring, end-of-life care, or telemonitoring
alone were excluded. Interventions were assessed using a
taxonomy of DMPs9 and scored for intensity and complex-
ity.15 Final consensus on findings, interpretation, and text
were agreed by all authors.
Information sources, search strategy, and study
selection
The following databases were searched from January 2017 to
May 2018: CINAHL through EBSCO, Cochrane, MEDLINE, and
Embase through Ovid. References in included articles were
hand searched. The following terms along with synonyms
and relevant terms were applied: HF, primary care, random-
ized controlled trials, disease management, nurse, and
multi-disciplinary. Titles and abstracts were reviewed by two
authors (F. K. and C. D.), and full-text papers were reviewed
by at least two of the authors.
Data process
The Cochrane data extraction form was revised to align with
the aims of the current review and pilot tested. Data were ab-
stracted and cross-checked by at least two authors indepen-
dently. Bias was assessed using the Cochrane Collaboration
tool16 by at least two authors on the following fields: (i) ran-
dom sequence generation, (ii) allocation concealment, (iii)
blinding of participants and personnel, (iv) blinded outcome
assessment, (v) selective outcome reporting, (vi) incomplete
outcome data, and (vii) other bias.
Results
Initial and updated searches found 7617 titles, with 6089 ti-
tles once duplicates were removed. The majority (5791)
were excluded following title review. Abstracts (192) were
screened in detail for eligibility, and 95 full-text papers were
reviewed. Reasons for exclusion of papers can be found in
Figure 1. An additional 20 papers from references were
reviewed. The final analysis included 18 studies in 18 papers
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with 5435 patients with HF, 1866 of whom were considered
by the study to have HFpEF (34%).
Inclusion of patients with heart failure with
preserved ejection fraction
Only one study focused exclusively on patients with HFpEF;
17 other studies included and documented numbers of pa-
tients characterized as HFpEF based on study criteria. When
studies stated that they included patients with HFpEF without
documenting percentage or number, authors were contacted
for information. The proportion of patients with HFpEF varied
from 18% to 100% and was variably defined in the studies
(Table 1). No studies defined HFpEF in line with the current
European Society of Cardiology (ESC) guidelines, which in-
clude the following criteria: signs and symptoms of HF, a left
ventricular EF ≥ 50%, elevated levels of natriuretic peptides
and either relevant structural heart disease (left ventricular
hypertrophy and/or left atrial enlargement), and/or diastolic
dysfunction on echocardiogram.8 Four studies included some
analysis specific to patients with HFpEF, with three of these in
comparison with HFrEF. Five studies had samples that were
predominantly patients with HFpEF (64–84%) as defined by
the study, although only one included discussion of issues
specific to HFpEF.
Heart failure with preserved ejection fraction
definition
The EF cut-off point for defining HFpEF ranged between ≥40%
and ≥50%. It is noticeable that the ESC recommended cut-off
point of EF ≥ 50% was used only in seven studies.17–23 Three
Figure 1 Results of the systematic search strategy and study selection process. DMP, disease management programme; HF, heart failure; HFpEF, heart
failure with preserved ejection fraction; LVSD, left ventricular systolic dysfunction.
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studies included patients labelled as HFpEF but without ex-
plicitly defining this population.24–26 The remaining nine stud-
ies used either >45%27–29 or 40%30–34 as EF criterion to
differentiate patients with HFpEF. The percentage of patients
with HFpEF defined by the studies ranged between 22% and
77%. By ESC criteria, these would be samples of patients with
both HF with mid-range EF (HFmrEF, EF 40–49%) and HFpEF,
which are considered two distinct clinical entities in the
guidelines.8
Interventions and study characteristics
Interventions varied by components, duration, methods of
delivery, intensity, complexity, and outcomes (Tables 2 and
3). All of the interventions were directed to patients, with
three including carers. Eleven of the study interventions were
delivered primarily by nurses with relevant experience or ad-
ditional training,17,20,21,25,26,28–31,33,34 six were multi-disciplin-
ary,18,19,22,27,32,35 and in one, it was unclear.23 All studies
included some component of education, behavioural or psy-
chosocial support, and self-management support. Only one
study included an exercise component delivered as part of
the study,17 although advice or referral for increasing physical
activity was frequently a component in other studies.
Telemonitoring was included in the intervention in two stud-
ies,18,22 and five provided medication adjustment by nurses
or via general practitioners.18–20,24,28 Patient assessment
was included in all but two studies,17,18 although the extent,
frequency, and type of assessment varied.
The duration of the interventions ranged from 3months to
over 2 years, and interventions in seven of the studies were
≥12 months.18,20,22,24,27,29,32 All studies included at least
one face-to-face encounter with patients, but telephone con-
tact was used in all to deliver some of the intervention. Home
visits were used in 11 studies.20,21,23,25,28–34 Outpatient or
clinical visits were included in all but two studies.26,27 The ma-
jority of studies were judged to be high in intensity and com-
plexity based on delivery of multiple components using
different methods of delivery and high frequency of contact,
and five were judged to be moderate.
Comparison
Seventeen of the 18 studies compared an intervention with
usual care, although two of these also included two interven-
tion arms varying by intensity and complexity.30,32 Usual care
was variably described across studies, and efforts to stan-
dardize usual care were made in only four studies.25,26,29,33
Controlling for patient contact as a confounding variable
was only described in one study.26 Stewart et al.28 tested
multi-disciplinary comprehensive care delivered by either
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Outcomes
The effect of disease management programmes on mortality
The most common primary outcome measure employed
was a composite of mortality and hospitalization, either
all-cause/all-cause (n = 4), all-cause/HF (n = 3),
cardiovascular/cardiovascular (n = 1), or cardiovascular/HF
(n = 1). All-cause mortality and/or all-cause hospitalizations
were secondary outcome measures in four studies respec-
tively, and one study employed an all-cause/HF composite
as a secondary objective. In the studies measuring mortality,
three reported a significant improvement.18,24,28,35 The pro-
portion of HFpEF patients in these studies was 67%,35
47%,18 and 27%,28 respectively. Of these studies, only
Stewart et al.28 reported separate HFpEF statistics (HFpEF de-
fined as those with EF> 45%) and found no difference in per-
centage with HFpEF by survived or died. Nine studies
reported no significant difference of their respective inter-
ventions on mortality between either intervention groups or
intervention and usual care.17,19,20,22,27,29,30,32,34 Kalter-
Leibovici and colleagues22 dichotomized findings by HF group
and found no significant difference by composite outcome
(all-cause mortality/HF hospitalization), or all-cause mortality
alone, and much wider confidence intervals in those with EF ≥
50%. Four of these nine studies without statistical significance
did report positive trends in mortality in favour of the inter-
vention.17,20,30,32 Dracup et al.30 added HF group (by EF <
40% or >40%) as a covariate and found no difference in out-
comes between groups.
The effect of disease management programmes on
hospitalizations
Most studies (88%) employed hospitalization(s) as an out-
come measure; the most common was all-cause hospitaliza-
tions (n = 8), HF-only hospitalizations (n = 5), HF and
all-cause (n = 2), or cardiovascular (n = 1). Only three re-
ported a statistically significant result.24,34,35 The remainder
reported either no impact17–20,27,30,33; positive trends in fa-
vour of the intervention such as shorter hospital stays,
prolonged time to hospitalization, and lower total numbers
hospitalized22,32; or trends towards higher hospitalizations
in intervention groups.23,28,29
The effect of disease management programmes on self-care
Nine studies evaluated the effect of the intervention on self-
care. There was significant variability in the self-care outcome
measures employed: the most frequently employed (n = 5)
was the Self-Care of Heart Failure Index15 followed by the Eu-
ropean Heart Failure Self-Care Behaviours Questionnaire (n =
3).36 Of the studies assessing effect on self-care (n = 9), four
reported a statistically significant positive effect,23,26,33 two
reported improvements that were not significant,20,25,30 and
one reported no impact,27 and in two studies, the effect
could not be ascertained from the publication.22,28
The effect of disease management programmes on condition-
specific quality of life
Heart failure quality of life was measured by either the Min-
nesota Living with Heart Failure Questionnaire37 (n = 5) or
the Kansas City Cardiomyopathy Questionnaire (KCCQ)38 (n
= 4). Three studies failed to demonstrate significant improve-
ment18,25,28; one study19 did not reach statistical significance
but demonstrated a clinically meaningful improvement in
quality of life as measured by KCCQ; and five studies reported
a statistically significant improvement in the intervention
arm.17,20,27,29,35
The effect of disease management programmes on anxiety,
depression, and sleep quality
Anxiety and depression were commonly measured and fea-
tured in nine of the 18 studies, and these were the primary
outcome in two studies.27,34 Freedland et al.27 demonstrated
that cognitive behavioural therapy plus an HF education pro-
gramme was superior to usual care plus an HF education pro-
gramme only, and this improvement was sustained over time.
Tsuchihashi-Makaya et al.34 similarly found that their home-
based DMP significantly improved psychological status com-
pared with usual care and was also sustained over time. Of
the seven studies examining anxiety or depression as a sec-
ondary outcome measure, impact of the intervention on ei-
ther variable, anxiety or depression, was undeterminable in
two publications29,31 and improved either significantly or clin-
ically in the intervention arm in five studies.17–19,21,22 One
study specifically focussed on improving sleep in HF pa-
tients21 and found both sleep quality and day-time sleepiness
levels significantly improved in the intervention arm.
Outcomes by heart failure with preserved
ejection fraction with ejection fraction ≥50%
If we use the ESC criterion that HFpEF includes an EF ≥ 50%,
then seven studies are of interest. The outcomes of mortality
and/or hospitalization were measured in six studies.17–20,22,23
Of these, only one had significantly fewer events in the
intervention group, specifically in all-cause mortality.18
Kalter-Leibovici et al.22 did not find a significant difference
in outcomes for DMP vs. control, and as noted previously,
the confidence intervals around the hazard ratios for HF hos-
pitalization and all-cause mortality were much wider for pa-
tients with HFpEF.
The single study that assessed self-care reported signifi-
cant improvement favouring the intervention group. The in-
tervention was efficacious in terms of health-related quality
of life (HRQoL) in two studies.17,20 In two studies, there was
no significant difference between intervention and control
groups in 3 and 6 months of HRQoL measured by the
KCCQ.18,19 Additionally, Bekelman et al.19 reported a lower
effect size of the intervention on the KCCQ for HFpEF
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compared with HFrEF (0.03 vs. 0.28). All five studies mea-
suring the outcomes of anxiety and/or depression demon-
strated significant improvement in favour of the
intervention arm.17–19,21,22
Outcomes by intervention provider
Six of the 11 studies with mainly nurse-led interventions had
outcomes related to mortality and/or hospitalization; one of
them demonstrated significant improvement in all-cause
mortality28 and another one in HF hospitalizations.34 Half of
the six nurse-led studies that assessed HRQoL reported im-
proved HRQoL in the intervention group as compared with
control.17,26,29 The majority of the nurse-led studies evaluat-
ing self-care changes achieved a significantly positive result
at least once during follow-up (including adjusted results)
when comparing the intervention to the control
group.25,26,30,33 Among the nurse-led studies, the interven-
tion group yielded superior results in relation to anxiety
and/or depression in three out of five studies.17,21,34 Five
studies employed a multidisciplinary approach in their inter-
vention: two reduced mortality and/or hospitalization18,35 in
the intervention group vs. control group, one improved
HRQoL35 in comparison with control group, and all three
studies measuring depression and/or anxiety had better re-
sults in the intervention group in this regard.18,19,22 None of
the multidisciplinary studies assessed self-care. In the study
of Freedland et al.,27 the intervention was delivered by be-
havioural therapists and was effective in improving HF quality
of life, anxiety, and depression. One study did not specify the
provider of the intervention.23
Assessment of bias
Most studies were rated as low risk in terms of random se-
quence generation. However, bias varied considerably across
other aspects with most studies being unable to conceal allo-
cation to intervention or usual care arms after randomization
from research team and patients. Almost all studies had
blinded outcome assessment, and most reported complete
outcome results (Table 4).
Discussion
In this systematic review, we found a limited number of con-
temporary studies of DMPs in HF that included or sufficiently
described patients with HFpEF and only one that was specif-
ically designed for this group. Across the studies, there was
significant heterogeneity in terms of the population, inter-
vention, comparisons, and outcomes that prohibited meta-
analysis. Definitions for HFpEF were variable with only seven
of the 18 studies employing an EF of ≥50%. This reflects the
lack of a universal approach in defining HFpEF even among
recent trials,39 despite the guidance provided by the ESC. In-
terventions were similarly heterogeneous with extensive var-
iability in the components included, mode of delivery,
complexity, and duration. Comparison groups received scant
attention; few studies sufficiently described attempts to stan-
dardize or account for potential confounding in ‘usual care’
control arms. In terms of outcomes, the most commonly



















Andryukhin (2010) Unclear Low High Low High High Higha
Bekelman (2015) Low Low High Lowb Low Low Low
Bekelman (2018) Low Low High Low Low High Low
Brotons (2009) Low Low High Low Low Low Low
Chang (2016) Unclear Low High Low Low Low High
Dracup (2014) Low Low Low Low Low Low Low
Freedland (2015) Unclear Low High Low Low Low Low
González-Guerrero (2014) Low Low High Lowc Low Low Low
Jaarsma (2008) Low Unclear High Low Low Low Low
Kalter-Leibovici (2017) Low Unclear High High Low Low High
Kwok (2008) Low Low High Low Low Low Low
Leventhal (2011) Low Low High Low Low Low High
Masterson Creber (2016) Unclear Unclear High Low Low High Low
Shao (2013) Low Low High Low Low Low High
Srisuk (2015) Low Low High Low Low Low Low
Stewart (2014) Low Unclear High Low Low Low Low
Tsuchihashi-Makaya (2014) Unclear Unclear Unclear Unclear Low Low Low
Young (2016) Low Low High Low Low Low High
aPositive change included no change from baseline.
bPositive change included improvement for 3 and 6 months.
cPositive change included improvement for primary outcome.
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and a minority demonstrated that the DMP had a statistically
significant impact on either outcome.
Four studies with both HFrEF and HFpEF reported results
separately for patients identified as HFpEF in the study, but
only two defined HFpEF using the recommended ESC crite-
rion of EF > 50%.19,22 Bekelman et al.19 (40% HFpEF, n =
121) found that the intervention had less effect on quality
of life in those with HFpEF compared with HFrEF. Kalter-
Leibovici et al.22 (18% HFpEF, n = 247) also found less effect
of the DMP and wide confidence intervals for HFpEF com-
pared with HFrEF; however, overall, there was no significant
difference by composite outcome, HF hospitalization, or all-
cause mortality by HF group. In the study exclusively HFpEF
(using EF ≥ 50%),15 the intervention group had improvement
or no deterioration in several cardiovascular risk factors, qual-
ity of life, depression, and left ventricular end-diastolic vol-
ume index compared with control. There was no statistically
significant difference between intervention and control on
cardiovascular events or mortality at 6 and 18 months. This
trial was innovative in including exercise sessions and
measuring specific echocardiographic parameters but none-
theless included recommendations for HFrEF medications
that have not been shown to improve event-free survival in
patients with HFpEF. Bias was also assessed as high on some
components (Table 4).
Programme components offer a useful framework to ex-
plore reasons for variable impact on outcomes assessed in in-
cluded studies.
Clinical assessment
Sixteen studies included either MDT or nurse-led clinical
assessment that then formed the basis of individualized HF-
specific treatment plans. None detailed exploration of co-
morbidity, clinical phenotyping, or comprehensive geriatric
assessment, although one DMP was delivered through a geri-
atric day-care hospital.35 Data from clinical trials have clearly
demonstrated the high incidence of co-morbidities in HFpEF
and effects of this has on outcome. The CHARM trial found
that demographic risk factors (age and sex) and non-cardiac
risk factors contributed more to mortality and morbidity out-
comes in patients with HFpEF (n = 1086 defined as EF> 40%),
while cardiac disease burden contributed more to outcomes
in those with HFrEF.40 If co-morbidities drive the develop-
ment of HFpEF through a systemic pro-inflammatory state
as currently postulated,41 then the focus on appropriate con-
trol of cardiovascular and non-cardiovascular co-morbid con-
ditions is essential.3,8,42
The ARISE-HF investigators recently presented a pragmatic
framework that includes profiling to determine concurrent
co-morbidities, identifying individualized priorities and pa-
tient-centred goals, supporting multi-professional home-
based case management, coordinating care, and emphasizing
self-care.43 Shah et al.3 devised an HFpEF treatment grid or-
ganized by predisposition phenotype (e.g. hypertension and
metabolic syndromes) and clinical presentation phenotype
(e.g. lung congestion and atrial fibrillation) to determine man-
agement based on the patient’s phenotypic features and co-
morbid conditions. Upadhya et al.44 have called for HFpEF to
be recognized as a true geriatric condition and suggested that
geriatric principles should be used in the treatment of HFpEF.
Educational/behavioural/self-management
interventions
Self-management interventions have previously been found
to reduce risk of the composite endpoint of HF-related hospi-
talization and all-cause death, HF-related hospitalization
alone, and result in a small improvement in HRQoL compared
with usual care.45 In this review, all studies incorporated ed-
ucational, behavioural, or self-care components designed to
improve self-management. Only three of nine studies mea-
suring self-care as an outcome demonstrated a statistically
significant improvement in self-care. Programme characteris-
tics, mechanisms of effect, and evidence for efficacy may ex-
plain this finding. In an individual patient data meta-analysis
of 20 trials of self-management support in patients with HF
(n = 5624), no specific programme characteristics were iden-
tified that consistently had a positive effect on multiple out-
comes. A 2016 systematic review and realist synthesis of
the main mechanisms of HF DMPs found that to be effective,
programmes should contain components that increase pa-
tient understanding of HF, self-care, self-efficacy,
family/caregiver involvement, psychosocial well-being, health
professional support, and technology use.46 Although many
studies encompassed components that harnessed one or
more of these mechanisms, no single programme compre-
hensively covered all. Finally, our knowledge of optimal life-
style behaviours and self-care in HFpEF is limited, and self-
care interventions for patients with HFpEF lack evidence of
effectiveness.
Exercise
Being physically active was advocated in most studies, but
only one study delivered an exercise intervention.17 Other
studies encouraged exercise as part of self-management edu-
cation and support, referred to formal exercise programmes
(although uptake not reported), and one23 measured activity
as part of a primarily telephone-delivered self-management
intervention. No significant difference between the groups
was found in activity, which was low in both groups.23 Exer-
cise is a promising but underutilized intervention in patients
with HFpEF. While data are limited, a meta-analysis of six tri-
als (n = 276 patients) showed that cardiorespiratory fitness
16 F. Kalogirou et al.
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and quality of life were significantly improved with exercise
compared with control. Clinical outcomes were not reported,
and the studies were of short duration (12–24 weeks).47 A
small study tested the effect of a calorie restricted diet, aer-
obic exercise training (primarily walking), a combination of
diet and exercise, or an attention control on 100 obese pa-
tients with HFpEF. At 24 weeks, the diet, exercise, and diet
+ exercise groups had significant improvements in exercise
capacity by peak VO2 (greatest increase in diet + exercise)
but no significant improvement on quality of life measured
by the MLHFQ. Diet significantly improved KCCQ scores, and
diet and exercise decreased body weight and improved
New York Heart Association class.48
Telemonitoring
Two studies in this review included telemonitoring as a com-
ponent of a DMP.18,22 Multiple studies of non-invasive
telemonitoring as the primary intervention in HF have been
conducted with inconsistent results. The latest guidelines on
management of HF have no recommendations for non-inva-
sive telemonitoring in management.8 A recent paper tested
a holistic and structured remote management intervention
involving a multi-disciplinary team (nurses, primary care phy-
sicians, cardiologists, other providers, and the patient),
telemonitoring, risk assessment, and tailored support and
management available 24 h or 7 days/week. The intervention
resulted in fewer days lost to unplanned cardiovascular hospi-
talizations and all-cause mortality compared with usual care
over 1 year. However, the sub-group analysis of patients with
EF > 45% (n = 537) showed no benefit between intervention
and usual care.49
Limitations
This systematic review has a number of limitations. Impor-
tantly, the varying and inconsistent definitions of HFpEF
(some samples included HFmrEF), heterogeneity of studies
with significant variation in the aims, interventions and out-
comes measured, ascertainment of the condition, and pro-
portion of patients with HFpEF limited our ability to
compare the studies directly, employ a meta-analysis, and
draw clear conclusions for this group of patients. In only six
studies, the percentage of patients with HFpEF exceeded
50%, and just four studies reported separate results for pa-
tients with HFpEF (including patients not meeting ESC guide-
line criteria for HFpEF). The search strategy may have failed
to retrieve relevant studies, as grey literature or reports in
languages other than English and Greek were not included.
Time restrictions were applied, and the search was not ex-
tended to all available databases. In DMPs, blinding of the re-
search team and participants is not feasible, which may bias
results in favour of the intervention group. Caution should
be used in the interpretation of findings and the results of
the current review especially given the lack of data for appro-
priately defined HFpEF.
Conclusions
Varying definitions of HFpEF (including patients with HFmrEF)
used in studies are a substantial limitation in interpretation of
findings, which may not reflect the effect of DMPs in HFpEF
patients. Although statistically significant or positive trends
in the primary outcomes were found in mortality, hospitaliza-
tion rates, self-care ability, HF knowledge, quality of life, anx-
iety, depression, and sleep, the evidence is not sufficiently
robust or consistent to draw substantive conclusions. We
have used programme components as a way of exploring
how impact may have been attenuated. Given that patients
with HFpEF are older and multi-morbid, DMPs targeting
HFpEF should not rely on a single-disease focus but provide
care that addresses predisposing and presentation pheno-
types of well-defined HFpEF and draws on the principles of
comprehensive geriatric assessment. Other components
could also be more targeted to HFpEF such as modification
of lifestyle factors for which there is emerging evidence,
rather than simply continuing the model of care used in
HFrEF. The reduced efficacy noted in contemporary HF DMP
studies may not only be due to improvements in usual care
but may reflect inclusion of heterogeneous patients with
HFmrEF and HFpEF who may not respond in the same way
as HFrEF to individual components. Based on current evi-
dence, HF DMPs may improve mortality, hospitalization rates,
self-care, and quality of life in patients with HFpEF; however,
further research specifically tailored to appropriately defined
HFpEF is required.
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